The Asia Pacific Transdermal Drug Delivery Systems Market would witness market growth of 5.4% CAGR during the forecast period (2022-2028).
Technological advancements such as the incorporation of mechanical arrays or microneedles in transdermal patches have provided further growth to the implementation of TDDS. The improvements include adjustments to transdermal patch designs, the addition of pressure-sensitive adhesives, and permeation enhancers, which have improved drug diffusion and boosted the reservoir's ability to hold more medication. Other improvements include reservoir-type transdermal patches and tiny, sophisticated transdermal patches that offer precise medicine doses.
In transdermal drug delivery systems more recently, microneedles have gained popularity, notably for the delivery of macromolecules or hydrophilic substances. The major skin barrier, the stratum corneum, can be crossed by microneedles, allowing access to the deeper layers of the epidermis. Skin permeability is greatly increased by this. Microneedles, in contrast to hypodermic injections, are minuscule enough to avoid coming into touch with the blood vessels and nerves in the dermis.
For a range of medication delivery applications, various kinds of microneedles with special qualities have been created. Solid microneedles can be utilized to improve permeability prior to drug application and are ideally suited for penetration. Hollow microneedles are utilized to make skin infusion routes for drugs. The medication coating on the surface of coated microneedles dissolves once they are inserted into the skin. In order to contain medications that completely dissolve in the skin and release their contained reagents, biodegradable and biocompatible polymer microneedles have also been developed.
In the Asia Pacific region, Japan turned out to be the country promoting transdermal drug delivery systems the most. This can be attributed to ongoing technological advancements, growing industry collaboration, and the expansion of market players' distribution networks. The older population of Japan has been on the rise for several years and has attracted the government's concern. A significant amount of healthcare, especially for the elderly is spent in the country.
The China market dominated the Asia Pacific Transdermal Drug Delivery Systems Market by Country in 2021; thereby, achieving a market value of $5,327.2 million by 2028. The Japan market is poised to grow at a CAGR of 4.8% during (2022-2028). Additionally, The India market would showcase a CAGR of 6.1% during (2022-2028).
Based on Application, the market is segmented into Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation and Others. Based on Type of Delivery System, the market is segmented into Passive and Active. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.
Technological advancements such as the incorporation of mechanical arrays or microneedles in transdermal patches have provided further growth to the implementation of TDDS. The improvements include adjustments to transdermal patch designs, the addition of pressure-sensitive adhesives, and permeation enhancers, which have improved drug diffusion and boosted the reservoir's ability to hold more medication. Other improvements include reservoir-type transdermal patches and tiny, sophisticated transdermal patches that offer precise medicine doses.
In transdermal drug delivery systems more recently, microneedles have gained popularity, notably for the delivery of macromolecules or hydrophilic substances. The major skin barrier, the stratum corneum, can be crossed by microneedles, allowing access to the deeper layers of the epidermis. Skin permeability is greatly increased by this. Microneedles, in contrast to hypodermic injections, are minuscule enough to avoid coming into touch with the blood vessels and nerves in the dermis.
For a range of medication delivery applications, various kinds of microneedles with special qualities have been created. Solid microneedles can be utilized to improve permeability prior to drug application and are ideally suited for penetration. Hollow microneedles are utilized to make skin infusion routes for drugs. The medication coating on the surface of coated microneedles dissolves once they are inserted into the skin. In order to contain medications that completely dissolve in the skin and release their contained reagents, biodegradable and biocompatible polymer microneedles have also been developed.
In the Asia Pacific region, Japan turned out to be the country promoting transdermal drug delivery systems the most. This can be attributed to ongoing technological advancements, growing industry collaboration, and the expansion of market players' distribution networks. The older population of Japan has been on the rise for several years and has attracted the government's concern. A significant amount of healthcare, especially for the elderly is spent in the country.
The China market dominated the Asia Pacific Transdermal Drug Delivery Systems Market by Country in 2021; thereby, achieving a market value of $5,327.2 million by 2028. The Japan market is poised to grow at a CAGR of 4.8% during (2022-2028). Additionally, The India market would showcase a CAGR of 6.1% during (2022-2028).
Based on Application, the market is segmented into Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation and Others. Based on Type of Delivery System, the market is segmented into Passive and Active. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Analgesics
- Hormone Replacement Therapies
- Hypertension
- Motion Sickness
- Smoking Cessation
- Others
By Type of Delivery System
- Passive
- Active
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Viatris Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Endo International plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Purdue Pharma L.P.
- Altaris
- Hisamitsu Pharmaceutical Co. Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Transdermal Drug Delivery Systems Market by Application
Chapter 4. Asia Pacific Transdermal Drug Delivery Systems Market by Type of Delivery System
Chapter 5. Asia Pacific Transdermal Drug Delivery Systems Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Viatris Inc.
- Bayer AG
- Boehringer Ingelheim GmbH
- Endo International plc
- GlaxoSmithKline plc
- Johnson & Johnson
- Novartis AG
- Purdue Pharma L.P.
- Altaris
- Hisamitsu Pharmaceutical Co. Inc.
Methodology
LOADING...
